FDA Approves Giredestrant Plus Everolimus for ESR1-Mutated Advanced Breast Cancer
The FDA has approved Genentech's oral drug giredestrant, sold as Wilserdly, with everolimus for ESR1-mutated advanced breast cancer. In the evERA trial, median progression-free survival was 10 months versus 5.5 months, but overall survival data remain immature and the label is limited to ESR1-mutated disease.
Freezing Instead of Cutting: FDA-Required Study of Breast Cancer Cryoablation Enrolls First U.S. Patients
Instead of removing small, low-risk breast tumors, a needle-based device freezes them in place. Its maker has started the larger U.S. study the FDA required, which will follow 400 older women for five years to see how often cancer returns.